CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-02 | Dar Zavain Director | Grant or award | +1,907 | 108,132 | ||
| 2025-01-02 | Li Dean Y Director | Grant or award | +1,647 | 77,350 | ||
| 2025-01-02 | Borgeson Blake Director | Grant or award | +1,734 | 7,067,847 | ||
| 2024-12-19 | Taylor Ben R Chief Financial Officer | Grant or award | +370,343 | 844,210 | ||
| 2024-12-19 | Taylor Ben R Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +740,686 | 740,686 | ||
| 2024-12-17 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −7,057 | $6.95 | $49K | 473,867 |
| 2024-12-16 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −15,668 | $6.04 | $95K | 480,924 |
| 2024-12-05 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 756,633 | ||
| 2024-12-05 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $7.12 | $142K | 736,633 |
| 2024-12-05 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 6,016,700 | ||
| 2024-12-04 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 756,633 | ||
| 2024-12-04 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $7.16 | $143K | 736,633 |
| 2024-12-04 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 6,036,700 | ||
| 2024-11-20 | Michor Franziska Director | Grant or award | +30,618 | 30,618 | ||
| 2024-11-20 | Michor Franziska Director | Grant or award | +15,335 | 45,953 | ||
| 2024-11-20 | Michor Franziska Director | Grant or award | +17,694 | 63,647 | ||
| 2024-11-20 | Michor Franziska Director | Grant or award | +41,390 | 105,037 | ||
| 2024-11-20 | Michor Franziska Director | Grant or award · Stock Option (Right to Buy) | +30,670 | 30,670 | ||
| 2024-11-20 | Michor Franziska Director | Grant or award · Stock Option (Right to Buy) | +15,286 | 15,286 | ||
| 2024-11-20 | Michor Franziska Director | Grant or award · Stock Option (Right to Buy) | +17,694 | 17,694 |
Page 12 of 41 · 805 trades